BACKGROUND: The cardiovascular (CV) benefits of lipid-lowering therapy in older adults with hypercholesterolemia and underlying risk factors for coronary artery disease (CAD) have been well documented. Significant reductions in the risk of myocardial infarction (MI) and coronary death have been demonstrated with statin therapy, benefits that are of particular relevance in patients with diabetes. Managed care interventions with prescribers have increased the use of selected drugs such as statins.
• Large cardiovascular (CV) outcome studies have shown significant reductions in the relative risk of death and major coronary events with the use of statins for secondary prevention. The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) trial demonstrated a 19% reduction in the risk of nonfatal myocardial infarction (MI) and coronary death with statin treatment in the elderly, and the Scandinavian Simvastatin Survival Study (4S) demonstrated a 34% reduction in the risk of coronary events in patients with coronary heart disease. The risk of coronary events was also significantly reduced in subgroups of women and patients of both sexes aged 60 years or older.
• Approximately one third of patients hospitalized with acute MI do not receive lipid-lowering medications at discharge despite the overwhelming weight of evidence in support of such therapy.
• Published information about programs to encourage appropriate use of statin medications is limited. In 1 randomized controlled trial, educational messaging delivered via rapid response e-mails to 14 primary care providers caring for 235 patients resulted in improved adherence to National Cholesterol Education Program (NCEP) guidelines, with statin prescription change rates of 15% for intervention patients versus 2% for controls at 1 month (P = 0.001), and the median months to statin prescription change was 0 for intervention patients versus 7.1 for controls (P = 0.005).
In a subgroup of patients with low-density lipoprotein cholesterol (LDL-C) > 130 mg per dL, the first post-intervention LDL-C level was lower for the intervention (119.0 mg per dL) than for the control (138.0 mg per dL) group (P = 0.04).
T he benefits of lipid-lowering therapy in patients with hypercholesterolemia and underlying risk factors for coronary artery disease (CAD) are well documented and are of particular importance in patients with diabetes. 1 Significant reductions in fatal and nonfatal cardiovascular (CV) events have been demonstrated in patients with and without CAD. [2] [3] [4] [5] Primary and secondary prevention of nonfatal myocardial infarction (MI) and CV death are the driving force behind the use of statins as a standard of care and the reason for their positioning as a first-line therapy in patients with hypercholesterolemia. [1] [2] [3] [4] [5] The West of Scotland Coronary Prevention Study demonstrated a 31% reduction in the risk of coronary events in patients with hypercholesterolemia but no past history of MI, while the Scandinavian Simvastatin Survival Study (4S) demonstrated a 34% reduction in the risk of coronary events in patients with coronary heart disease. 2, 3 The significant risk reductions seen in 4S extended to subgroups consisting of women and patients of both sexes aged 60 years or older. Separately, in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) trial, the use of pravastatin was associated with a 19% reduction in the risk of nonfatal MI and coronary death. 6 Clearly, the protective effect of statins is evident in patients across a wide range of ages and cholesterol values, regardless of gender. 1, 7, 8 Meta-analyses of the numerous statin outcomes studies also underscore the value of lowering low-density lipoprotein cholesterol (LDL-C) and highlight a relationship between LDL-C reduction and decreases in the risk of coronary events. 9 This relationship holds true in patients hospitalized with acute MI, a population in which the cost-effectiveness of secondary prevention via statin-medicated LDL-C reduction has been amply demonstrated. 2, 3, 7, 10, 11 Up to 93% of post-MI patients require lipid-lowering medications after discharge despite intensive diet and exercise counseling and monitoring. 12 Nevertheless, a significant proportion of patients hospitalized with acute MI do not receive lipid-lowering medications at discharge despite the overwhelming weight of evidence in support of such therapy. [13] [14] [15] [16] Fonarow et al. found that only one third of patients hospitalized with acute MI were discharged on lipid-lowering medications as recorded in the medical record. 13 A more recent analysis revealed that 37% of patients hospitalized with an acute coronary syndrome do not receive a statin after discharge. 17 The cost of this oversight in terms of morbidity, mortality, and increased utilization of medical services has yet to be fully quantified, although the possibility of risk reduction alone clearly warrants the provision of care. In addition, the magnitude of benefit with lipid-lowering medications in this particular patient population matches or exceeds benefits associated with other secondary prevention medications such as aspirin, beta-blockers, and angiotensinconverting enzyme inhibitors. 13 Special consideration should also be given to patients with diabetes because of a significantly increased risk of developing CV disease. Type 2 diabetes, which affects approximately 20 million Americans, is associated with atherogenic dyslipidemias and poorer prognoses once clinical CV disease develops. After lifestyle modifications, current guidelines from the American Diabetes Association (ADA) place the highest treatment priority on LDL-C reduction, followed by raising high-density lipoprotein cholesterol (HDL-C) levels and lowering triglyceride levels. 18 Statins are considered first-line agents for reaching National Cholesterol Education Program (NCEP)/ADA LDL-C targets and have been shown to reduce major coronary events in patients with diabetes. 6, 8 Currently, there is limited published information about clinical programs that successfully encourage the appropriate use of statin medications. However, Lester et al. conducted a prescriber-targeted intervention that was associated with significantly improved adherence to NCEP guidelines and lower LDL-C levels in the intervention cohort; the intervention leveraged electronic technologies to facilitate message dissemination and order entry and fulfillment. 19 Similar mail-based programs may also be effective at modifying prescriber behavior and increasing appropriate utilization of statins in patients at risk for coronary events.
In order to increase the use of statins among members with diabetes or CAD, a national pharmacy benefit management (PBM) company implemented an intervention aimed at prescribers as part of a broader medication therapy management program (MTMP). This article describes the effect of this intervention with prescribers on increasing the initiation of statin therapy among MTMP members with diabetes or CAD. Table 1 ). Because medical claims data were not available for PDP members, disease conditions for PDP members were identified using member-reported data obtained from a member questionnaire. The questionnaire was sent only to those PDP members who met the first 2 qualification criteria for the MTMP. To be eligible for the MTMP, the member must have returned the questionnaire and indicated that he or she had a history of at least 3 of the 5 diseases of interest. A comparison of the methodology used to identify disease conditions for MA-PD and PDP members is shown in Table 1 .
After they were identified as meeting the 3 MTMP criteria, members were eligible for the intervention if they were identified as having diabetes or CAD (patients with a previous MI were considered as having CAD) and they had no pharmacy claims for a statin (GPI codes 3940xx or 3999xx) during the identification period (January 1, 2006, through June 30, 2006). Members were excluded from the intervention if they had previously declined to participate in the MTMP. A flowchart of the selection process is shown in Figure 1 .
Criteria were developed to identify prescribers who received the intervention. For members with CAD, the most recent prescriber of any CV agent was identified. If no CV agents were prescribed, the most recent prescriber of any chronic medication was identified. For members with diabetes and members with diabetes plus CAD, the most recent prescriber of any antidiabetic medication was identified. If no antidiabetic medications were prescribed, the most recent prescriber of any chronic medication was identified.
A total of 1,340 members and 1,275 prescribers were identified for the intervention. On August 18, 2006 , the identified prescribers were mailed a patient-specific report that highlighted the members under his or her care that could benefit from statin therapy. The report also included a section for prescriber feedback and a prescriber educational booklet on statin therapy.
Effect of an Intervention to Increase Statin Use in Medicare Members
Who Qualified for a Medication Therapy Management Program
Program Evaluation
Electronic medical and/or pharmacy claims for members participating in MA-PD and PDP plans during 2006 were used to evaluate the intervention. Institutional Review Board (IRB) exemption certification was obtained from Independent Review Consulting, Inc., an external IRB, prior to conducting the analysis. To help interpret the impact of the program, a comparison group that did not receive the intervention was identified and was compared with the intervention group. Since all members who met the program's inclusion and exclusion criteria were targeted for an intervention, the comparison group was selected from MA-PD members who met all of the MTMP criteria except the presence of at least 3 of 5 chronic diseases of interest (i.e., hypertension, hyperlipidemia, CAD, congestive heart failure, and diabetes). Similar to the intervention group, the comparison group consisted of members with diabetes and/or CAD (including prior MI) but who did not have a pharmacy claim for a statin medication during the identification period ( Figure 1 ). Members were followed for the 4-month period following the date of the intervention (e.g., the follow-up period). Members were excluded from the analysis if they were not continuously enrolled with the health plan for the entire identification and follow-up periods (i.e., from January 1, 2006, through December 18, 2006) .
The primary outcome of interest was the percentage of members who had a pharmacy claim for a statin medication during the follow-up period. Logistic regression was used to determine the likelihood of starting a statin in the follow-up period after controlling for possible confounding factors such as age, gender, geographic state, and Chronic Disease Score (CDS). The CDS, developed by Von Korff et al., was used as a measure of comorbidity and was calculated using pharmacy claims data from the identification period. The CDS is weighted based on the number of different chronic diseases under treatment, with a higher score representing a more severe burden of comorbidity. 20 To estimate the number of interventions needed to prevent 1 cardiac event, we first calculated (A) the number of members requiring interventions for our program to produce 1 statin initiation; this is the reciprocal of the difference between the statin initiation rates in the intervention and comparison groups. We then calculated (B) the number needed to treat with statins to avoid 1 major coronary event as the reciprocal of the improvement attributable to statin use based on findings from the 4S trial, where improvement was defined as the rate of major coronary events (e.g., coronary death, nonfatal definite or probable MI, silent MI, or resuscitated cardiac arrest) for a placebo group minus the rate for a statin-treated group. 2 We chose to use the 4S trial instead of the PROSPER trial, 6 which measured cardiac event reduction in a group of patients aged 70 to 82 years because the PROSPER population was approximately 5 years older on average than our population (75 years vs. 70 years) and included some lower-risk patients than our population. Patients were required to have CAD, diabetes, or MI to be eligible for our intervention, whereas patients with hypertension only or smoking history only were able to be enrolled in PROSPER. In PROSPER, only 44% of patients had vascular disease and 11% had diabetes, while all of our intervention population had either vascular disease or diabetes. The estimated number of members requiring intervention to prevent a cardiac event was the product of (A) × (B), where (A) is the number of interventions needed to produce a statin initiation, and (B) is the number of statin initiations needed to avoid 1 coronary event.
After estimating the number of interventions necessary to avoid a major coronary event, the costs avoided by conducting the intervention were calculated as (1) the cost of a major coronary event minus (2) the sum of the program costs plus the costs of statin treatment for a 5.4-year period (the median follow-up period for the 4S study) for the estimated count of members initiating a statin as a result of the program. Costs of a major coronary event were obtained from the literature, where the first-year costs following an acute MI or intermediate coronary syndrome have been estimated to be $22,528, using 1999 through 2001 data from a large U.S. managed care organization. 21 These published costs were inflated to 2007 values ($28,990), using the medical care component of the Consumer Price Index. 22 Statin costs were measured for MA-PD and PDP members with a claim for a statin between July and September 2007. For each statin user identified, 6 months of claims data were analyzed to measure the median pharmacy ingredient costs over a 6-month period; costs were annualized by multiplying by 2.
Data extraction and statistical analysis were conducted using SAS Version 9.1 (SAS Institute, Inc., Cary, NC). Means were compared by t-tests and percentages were compared using Pearson chi-square tests. All comparisons were 2-sided and performed at a 0.05 level of significance.
■■ Results
After excluding members who were not continuously enrolled during the identification and follow-up periods (i.e., from January 1, 2006, through December 18, 2006) , the evaluation population consisted of 1,144 intervention members (468 MA-PD and 676 PDP) and 700 MA-PD comparison members (Table 2) . Mean (SD) age was 69.5 (12.3) years for the intervention group and 70.7 (12.0) years for the comparison group (P = 0.042). Geographic distribution was different for the 2 groups, with the majority of the comparison group residing in California compared with the majority of the intervention group residing in states other than Arizona, California, or Texas (e.g., Illinois, Florida, and Colorado). The intervention and comparison groups were similar with respect to gender and CDS.
During the follow-up period, 12.1% of members targeted for the intervention filled a prescription for a statin medication compared with 7.3% of comparison members (P = 0.001) ( Table 2) . After adjusting for age, gender, CDS, and geography, the odds of initiating a statin medication were 65% higher (adjusted odds ratio
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[OR] = 1.65; 95% confidence interval [CI] = 1.15-2.36; P = 0.006) for the intervention group than for the comparison group (Figure 2 ). The variables of age, gender, CDS, and geography did not significantly predict members who were likely to start a statin. Analysis of the number of interventions needed to prevent 1 cardiac event showed that prescribers for 20 members would need to be contacted to result in 1 statin initiation, and an estimated 11 members would need to be treated with a statin medication for a median of 5.4 years in order to avoid 1 major coronary event ( Table 3) . As a result, it would be necessary to conduct the intervention with prescribers of 220 members to avoid 1 major coronary event.
After subtracting the costs for statin medication and program administration from the major coronary event costs, the costs avoided by conducting the intervention in 220 members (enough members to avoid a major coronary event) were estimated to be $12,323. Thus, costs avoided by preventing 6 major coronary events among 1,340 members would total more than $73,000 (Table 4) .
■■ Discussion
A statin intervention aimed at prescribers of MTMP members with diabetes or CAD was successful in increasing statin medication use among members at higher risk for CV events. After controlling for age, gender, level of comorbidity, and the geographic state where the member resides, members who received the intervention were 65% more likely to start a statin medication than members who did not receive the intervention. Analysis of estimated coronary event costs associated with the intervention indicated that there is potential for cost savings associated with the intervention and should alleviate concerns that the intervention may increase health care spend.
These results are consistent with the findings of a randomized controlled trial conducted by Lester et al., which demonstrated 
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a positive change in statin medication prescribing following a prescriber-targeted intervention. Educational messaging delivered via rapid response e-mails to 14 primary care providers caring for 235 patients resulted in both an increase in adherence to NCEP guidelines (statin prescription change rates were 15% for intervention patients vs. 2% for controls at 1 month, P = 0.001; median months until statin prescription change was 0 vs. 7.1, respectively, P = 0.005) and a decrease in LDL-C in patients with elevated cholesterol levels (post-intervention levels of 119.0 mg per dL for intervention patients vs. 138.0 mg per dL for controls, P = 0.04). 19 Although the intervention leveraged electronic technologies to facilitate message dissemination and order entry and fulfillment, it is reasonable to assume that mail-based programs would be similarly effective at modifying prescriber behavior and increasing appropriate utilization of statins. In contrast, interventions with members to increase the appropriate use of statin medications have not been so successful. A nurse-managed disease management program that provided telephone and mail communications with members did not demonstrate an improvement in statin medication utilization during the first year after an MI. 23 The proportion of members who used a statin during the first year post-MI was the same for 24 further research is necessary to examine best methods for improving medi cation use in these members. If less intensive and less costly targeted interventions focusing on prescribers can have an equal or greater impact on improving medication use outcomes for members as high-touch member interventions, such interventions are worth examining and implementing in large populations.
Limitations
Finding a similar comparison group creates challenges. For example, it is not acceptable for a health plan to withhold the intervention from MTMP members who are identified as needing treatment with a statin medication. Therefore, a comparison group had to be selected from outside the MTMP population. While differences in the identification criteria for the intervention and comparison groups were minimized as much as possible, it is possible that members selected for the comparison group had different clinical characteristics that may have influenced the rate of starting a statin medication.
Second, the comparison group differed from the intervention group in several potentially important ways. The comparison group only contained MA-PD members, while the intervention group consisted of MA-PD and PDP members. Medical claims were not available for PDP members. Accordingly, among PDP members who were potentially eligible for MTMP, the identification of the presence of certain specific diseases required the use of member-reported data, which were not solicited among MA-PD members. Nonetheless, there is no reason to suspect that health plan type (PDP and MA-PD) would influence the likelihood of starting a statin medication; the percentage of intervention members who filled a prescription for a statin medication during the follow-up period was similar for MA-PD and PDP members (12.4% vs. 11.8%).
In addition to the fact that the comparison group members were in MA-PD plans only, the comparison members did not have to meet the requirement of at least 3 of the following chronic diseases: hypertension, hyperlipidemia, CAD, congestive heart failure, and diabetes. Thus, the comparison group was left with relatively fewer members with CAD and more members with diabetes than the intervention group. Distributions of diabetes and CAD for the intervention group and comparison group were as follows: diabetes and no CAD was present in 52% of the intervention group and 93% of the comparison group, CAD and no diabetes was present in 18% of the intervention group and 5% of the comparison group, and diabetes plus CAD was present in 30% of the intervention group and 2% of the comparison group. Even though it might be argued that the lower rate of initiating statin therapy in the comparison group was the result of the comparison group consisting of a greater proportion of members with diabetes, a post-hoc analysis of the subgroup of members with diabetes and no CAD found that this was not the case, with the initiation rate of statin therapy higher for the intervention group (60 of 592 members initiated a statin, 10.1%) than the comparison group (44 of 653 members initiated a statin, 6.7%; P = 0.031). Additionally, even though the intervention group was required to have more stringent requirements on the presence of specific comorbid conditions, the level of comorbidity was not significantly different for the overall intervention patients than the comparison patients (CDS 7.3 vs. 7.2, respectively).
Third, while this intervention can easily be conducted in populations where a health plan or PBM has both pharmacy and medical claims, the intervention is more difficult to implement where only pharmacy claims are available. We collected memberreported data to help identify which PDP patients may be eligible for this intervention, but member-reported data may be difficult to collect and may not always be reliable. Using drug proxies for identifying diseases through pharmacy claims is feasible but may not be accurate in identifying certain conditions. For example, the sensitivity and specificity of using pharmacy claims to identify members with diabetes may be higher than the sensitivity and specificity of using pharmacy claims to identify members with CAD. In addition, it is not possible to identify from claims data all of the members with a contraindication to a statin (e.g., liver disease, myopathy).
Fourth, a 4-month period following the intervention was used to evaluate response to the intervention. In some cases, this follow-up period may have been too short to evaluate the impact of the program because members may only visit their physician every 6 months or longer. However, if a longer follow-up period was used to evaluate the intervention, there may have been influences other than the intervention program that led a member to start a statin.
Fifth, we did not measure actual costs other than statin drug cost and administrative cost for the mailing to prescribers. Actual health plan costs for a major coronary event may be higher or lower than our estimate. We also did not assess actual physician visit costs, including any laboratory or other monitoring costs, that might be precipitated by the addition of statin drug therapy. Actual median statin drug cost of $22.92 per month suggests a large proportion of patients received generic statins, and actual drug costs will be higher or lower for other health plans depending on the generic dispensing ratio for statins.
Finally, we did not have access to data that would permit reporting of the proportion of Medicare-Medicaid dual-eligible beneficiaries in the present study.
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■■ Conclusion
This analysis shows that an intervention with prescribers of high-risk, high-cost Medicare Part D members can increase the use of a statin medication. This intervention with prescribers will increase pharmacy costs for statin drugs with the expectation that major CV events will be avoided as a result of increased use of statin drugs in this high-risk population of Medicare MTMP members with diabetes or CAD.
